Summ aryBeginning in 1964 we used mouse-foot-pad inoculations to monitor the loss in numbers of viable My cobacterium leprae that occurs when the patient begins antileprosy therapy.Our studies eventually involved patients at the US Public Health Service Hospital in San Francisco and the Leonard Wood Memorial facilities in Cebu, Philippines and mouse-foot-pad laboratories in San Francisco and Cebu, as well as Atlanta.We found that to monitor short-term therapeutic trials, the mouse-foot-pad method was the most efficient one available , in the sense that it required the smallest number of patients.All the results are compiled here in a standard form of presen tation to facilitate comparisons between trials and regimens.A table is provided for statistical consideration of results such as these .Mos t of th e resul t s to be present ed ha ve already been publishe d, bu t th eir collection in one place in a standar d fo rm may be helpful.Beginning in 1964 Levy and I, in collaboration with Fasal , (Levy and Fasal were then at the US Public Health Service Hospital in San Francisco) began to employ mouse-foot pad inoculations to monitor the decrease in numbers of viable My cobacteri um leprae that occur when the patient begins antilepro sy therapy .We already knew from the earliest mouse-fo ot-pad days that the bacilli fro m untreated patients were regularly infective fo r mice and that those from patients who had been *Originally presented at the October 1980 meeting of the THELEP Scientific Working Group in Geneva , at which it was agreed to submit papers for publication in both Leprosy Review and In ternational Journal of Leprosy.It is our understanding that similar publications will be printed in the December 1981 issue of IlL.
No takes yet. Share an insight, caveat, or question.
Charles C. Shepard (1981) studied this question.